Reviews/P2Y12 Antiplatelets/P2Y12 monotherapy after short DAPT reduces bleeding in ACS patients
Deescalation · P2Y12-DESC-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
This claim asks whether dropping aspirin and keeping only the second blood-thinner, after a brief initial period on both, lowers bleeding in people treated for a heart attack or unstable angina. Several dedicated trials in these patients point the same way: fewer bleeding events when aspirin is stopped after a short run-in on both drugs [10][20][7][8]. Two of the trials hid which drug patients were on, which removes the worry that doctors simply reported bleeding differently when they knew the treatment [6][10]. The panel noted real caveats, such as some trials being open-label and some mixing in patients without a recent heart attack [19][21], but these touch the edges rather than the core bleeding finding. One trial that removed aspirin from the very start, with no short run-in at all, found no bleeding benefit, which marks where the claim stops holding [11]. The consistency across different countries and trial designs is what the panel leaned on.
Four acute coronary syndrome trials report lower clinically relevant or major bleeding with P2Y12 monotherapy after a short DAPT course: ULTIMATE-DAPT [10] (2.1% vs 4.6%, HR 0.45), TICO [20] (1.7% vs 3.0%, HR 0.56), TARGET-FIRST [7] (2.6% vs 5.6%, HR 0.46) and NEO-MINDSET [8] (2.0% vs 4.9%). TWILIGHT [6], a double-blind trial, shows the same direction (4.0% vs 7.1%, HR 0.56), as does SMART-CHOICE [19] (2.0% vs 3.4%, HR 0.58) in a broader PCI population. The two placebo-controlled double-blind trials [6][10] reproduce the reduction, which addresses the concern that open-label designs inflate the comparator arm's bleeding count. SHARE [9] agrees in direction (0.2% vs 0.8%) but is not statistically significant. The contested point: The division is not over the bleeding reduction itself but over its boundaries: whether open-label adjudication inflates the effect [20][7][8][19], whether mixed PCI populations dilute the ACS-specific reading [6][19][21], and how far a potent-inhibitor, ticagrelor-dominated evidence base generalises to P2Y12 inhibition framed generically [21]. STOPDAPT-3 [11] marks the outer edge, showing no bleeding reduction (4.47% vs 4.71%) when aspirin is removed from the outset with no short DAPT run-in.
All 22 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from P2Y12 Antiplatelets, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
Four of the key ACS trials (TICO [20], TARGET-FIRST [7], NEO-MINDSET [8], SMART-CHOICE [19]) are open-label, so unblinded bleeding adjudication may inflate the DAPT-arm event count; however the two double-blind placebo-controlled trials TWILIGHT [6] and ULTIMATE-DAPT [10] reproduce the effect.
Population purity: TWILIGHT [6] includes ~35% chronic coronary syndrome and SMART-CHOICE [19] / STOPDAPT-2 [21] are mixed PCI cohorts, diluting the ACS-specific claim, though ULTIMATE-DAPT [10], TICO [20], TARGET-FIRST [7] and NEO-MINDSET [8] are ACS-dedicated.
Where it remains uncertain. Several supporting trials are open-label [20][7][8][19] or mixed PCI populations [6][19][21], and the benefit depends on a genuine short DAPT run-in, absent in aspirin-free STOPDAPT-3 [11], which found no bleeding reduction.
Aleatory
Bleeding events are few in several trials, e.g. SHARE [9] (0.2% vs 0.8%), leaving play-of-chance imprecision around small absolute differences.
Epistemic
TICO [20], TARGET-FIRST [7], NEO-MINDSET [8] and SMART-CHOICE [19] are open-label, so unblinded bleeding ascertainment may inflate the comparator arm.
Inferential
TWILIGHT [6] includes ~35% chronic coronary syndrome and SMART-CHOICE [19] and STOPDAPT-2 [21] are mixed PCI, so inferring a pure-ACS effect from them requires a step beyond the enrolled populations.
The load-bearing papers from a corpus of 22, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Double-blind high-risk PCI RCT (TWILIGHT): bleeding reduced after 3mo DAPT
“the incidence of the primary end point was 4.0% among patients randomly assigned to receive ticagrelor plus placebo and 7.1% among patients assigned to receive ticagrelor plus aspirin (hazard ratio, 0.56; 95% confidence interval [CI], 0.45 to 0.68; P<0.001)”
Panel auditInternal validity: high · scope of inference: High-risk PCI patients (bleeding or ischemic risk) after 3 months of DAPT, not an ACS-only cohort.Key limitations: population not ACS-specific · high-risk enrichment · ticagrelor only
Acute-MI RCT (TARGET-FIRST): bleeding superiority after 1mo DAPT
“BARC type 2, 3, or 5 bleeding occurred in 2.6% of the patients in the P2Y12-inhibitor monotherapy group and in 5.6% of those in the dual antiplatelet therapy group (hazard ratio, 0.46; 95% CI, 0.29 to 0.75; P = 0.002 for superiority)”
Panel auditInternal validity: high · scope of inference: Low-risk acute MI patients after early complete revascularization and 1 month event-free DAPT.Key limitations: open-label · low-risk enriched population
ACS RCT (NEO-MINDSET): potent P2Y12 mono reduces bleeding
“Major or clinically relevant nonmajor bleeding had occurred in 33 patients (Kaplan-Meier estimate, 2.0%) in the monotherapy group and in 82 patients (Kaplan-Meier estimate, 4.9%) in the dual antiplatelet therapy group (absolute risk difference, -2.97 percentage points; 95% CI, -4.20 to -1.73)”
Panel auditInternal validity: high · scope of inference: ACS patients with aspirin withdrawal within days of PCI rather than after a defined short DAPT course.Key limitations: near-immediate aspirin withdrawal, not post short-DAPT · ischemic noninferiority not met · open-label
The no-aspirin group was not superior to DAPT for major bleeding at 1 month.
Panel auditInternal validity: high · scope of inference: ACS or high-bleeding-risk patients with immediate aspirin-free monotherapy from the time of PCI.Key limitations: no short-DAPT period · low-dose prasugrel (Japanese dosing) · excess stent thrombosis signal
4 of 22 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Multiple independent RCTs including blinded, placebo-controlled trials converge on a bleeding reduction directly matching the claim's outcome, held at the Established floor to respect open-label and mixed-population caveats.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Blinded ACS-only bleeding trial. Most supporting ACS trials are open-label, leaving ascertainment bias unresolved for the bleeding endpoint [20][7][8]. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A double-blind, placebo-controlled trial restricted to ACS comparing P2Y12 monotherapy after short DAPT with continued DAPT, adjudicating bleeding blind.
Open question: How much of the measured bleeding reduction in open-label ACS trials is attributable to unblinded ascertainment rather than a true treatment effect? Why it is still open: TICO [20], TARGET-FIRST [7], NEO-MINDSET [8] and SMART-CHOICE [19] are open-label, and only [6] and [10] are blinded.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19